Details of the Drug

General Information of Drug (ID: DMKLMG6)

Drug Name
KN035
Synonyms Envafolimab
Indication
Disease Entry ICD 11 Status REF
Pleomorphic sarcoma 2B54 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Advanced malignancy 2A00-2F9Z Phase 1 [3]
Drug Type
Antibody
Cross-matching ID
UNII
ES1M06M6QH
DrugBank ID
DB15769
TTD ID
D0GF2R
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pleomorphic sarcoma
ICD Disease Classification 2B54
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04480502) ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04891198) ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
3 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.